ESR1 and gastric cancer: Growing evidences revealed that DDX5 is significantly associated with tumorigenesis.1, 2 It is overexpressed in colorectal3, gastric4, breast, and prostate tumours and is associated with tumour progression.5, 6 In addition, it acts as a coactivator of several transcription factors, including β‐catenin, p53, oestrogen receptor alpha, AKT signalling pathway, c‐Myc, and androgen receptors.7, 8 Recent study also showed that DDX5 is significantly elevated in gastric cancer and co‐excited the mTOR signalling pathway to enhance the growth of gastric cancer cells.